8-K: Neurocrine Biosciences Launches CRENESSITY for Congenital Adrenal Hyperplasia

Neurocrine Biosciences has announced the commercial availability of CRENESSITY in the U.S. for the treatment of classic congenital adrenal hyperplasia.

Summary

• Neurocrine Biosciences has launched CRENESSITY (crinecerfont) in the United States.
• CRENESSITY is approved as an adjunctive treatment to glucocorticoid replacement for controlling androgens in patients with classic congenital adrenal hyperplasia (CAH).
• The treatment is available for both adult and pediatric patients aged four years and older.
• CRENESSITY is a first-in-class therapy that directly reduces adrenocorticotropic hormone and downstream adrenal androgen production.
• The wholesale acquisition cost for a 30-day supply is approximately $38,333, with a reduced cost of $19,167 for pediatric patients under 20 kilograms.
• Neurocrine Biosciences expects 90% of patients will have a monthly copay of $12 or less.
• The drug is available in capsule and oral solution forms, with specific dosing guidelines based on age and weight.
• CRENESSITY is exclusively available through PANTHERx Rare, a specialty pharmacy, with 24/7 support from CAH-trained pharmacists.
• Neurocrine Access Support provides free, comprehensive assistance to patients, caregivers, and healthcare providers.

Sentiment

Score: 8

Explanation: The document is positive due to the launch of a new, first-in-class treatment for a rare condition, with a comprehensive support program and a high expectation of patient access. However, the high cost of the drug and potential side effects temper the overall sentiment slightly.

Positives

• CRENESSITY is a first-in-class therapy that directly reduces adrenocorticotropic hormone and downstream adrenal androgen production.
• It allows patients to potentially reduce their glucocorticoid dosage while maintaining or improving androgen levels.
• The company has established a comprehensive patient support program, Neurocrine Access Support.
• The drug is available in multiple formulations (capsules and oral solution) to cater to different patient needs.
• The company expects 90% of patients will have a monthly copay of $12 or less.

Negatives

• The wholesale acquisition cost for CRENESSITY is high, at approximately $38,333 for a 30-day supply.
• Patients must continue glucocorticoid therapy for cortisol replacement while using CRENESSITY.
• The drug has potential side effects, including allergic reactions and the risk of adrenal insufficiency if glucocorticoid dosage is insufficient.

Risks

• There are risks and uncertainties associated with the commercialization of CRENESSITY.
• The company faces risks related to third-party manufacturing and development.
• There is a risk that CRENESSITY may not receive adequate reimbursement from third-party payors.
• Competitive products and technological changes may limit demand for CRENESSITY.
• There is a risk of adverse decisions from regulatory authorities regarding CRENESSITY.

Future Outlook

The company anticipates that CRENESSITY will provide significant benefits to patients with classic congenital adrenal hyperplasia, and they are committed to supporting patient access to the treatment. The open-label extension treatment portions of the CAHtalyst studies are ongoing.

Management Comments

• Kyle W. Gano, Ph.D., Chief Executive Officer, Neurocrine Biosciences, stated that individuals with CAH and their families have faced ongoing challenges with managing the condition with high-dose steroids alone for the past 70 years.
• Kyle W. Gano, Ph.D., also mentioned that they are proud to now provide CRENESSITY to the community and are committed to supporting patients in obtaining treatment.

Industry Context

This announcement is significant as CRENESSITY is the first-in-class therapy for classic CAH that directly reduces adrenocorticotropic hormone and downstream adrenal androgen production, offering a new treatment option for a condition that has historically been managed with high-dose steroids. This launch positions Neurocrine Biosciences as a leader in the treatment of rare neuroendocrine disorders.

Comparison to Industry Standards

• Traditional treatments for CAH have relied on high-dose glucocorticoids, which often lead to significant side effects.
• CRENESSITY offers a novel approach by targeting the underlying hormonal imbalance, potentially reducing the need for high-dose steroids.
• The CAHtalyst studies, which supported the FDA approval, are the largest-ever clinical trial program in classic CAH, indicating a robust evidence base for the drug's efficacy.
• Compared to other treatments, CRENESSITY's mechanism of action is unique, as it is a corticotropin-releasing factor type 1 receptor (CRF1) antagonist, which directly reduces ACTH levels.

Stakeholder Impact

• Patients with classic congenital adrenal hyperplasia will have a new treatment option that may reduce their reliance on high-dose steroids.
• Healthcare providers will have a new tool for managing CAH.
• Shareholders may see a positive impact from the commercialization of CRENESSITY.
• The company's employees will be involved in the launch and support of the new product.

Next Steps

• Neurocrine Biosciences will continue to support patients in obtaining treatment with CRENESSITY through their comprehensive assistance program.
• The open-label extension treatment portions of the CAHtalyst studies are ongoing.

Key Dates

Keywords

CRENESSITY, congenital adrenal hyperplasia, CAH, crinecerfont, Neurocrine Biosciences, glucocorticoid, androgen, PANTHERx Rare, adrenocorticotropic hormone, ACTH